1. Home
  2. TRDA vs NKLR Comparison

TRDA vs NKLR Comparison

Compare TRDA & NKLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$13.05

Market Cap

481.6M

Sector

Health Care

ML Signal

N/A

NKLR

Terra Innovatum Global N.V. Ordinary shares

N/A

Current Price

$4.15

Market Cap

426.7M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
TRDA
NKLR
Founded
2016
2018
Country
United States
Italy
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
481.6M
426.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TRDA
NKLR
Price
$13.05
$4.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$20.00
$15.00
AVG Volume (30 Days)
191.6K
382.1K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,421,000.00
N/A
Revenue This Year
$51.37
N/A
Revenue Next Year
$46.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$3.73
52 Week High
$12.93
$12.43

Technical Indicators

Market Signals
Indicator
TRDA
NKLR
Relative Strength Index (RSI) 62.11 42.21
Support Level $9.59 $3.90
Resistance Level N/A $5.25
Average True Range (ATR) 0.85 0.34
MACD 0.11 -0.00
Stochastic Oscillator 90.08 23.08

Price Performance

Historical Comparison
TRDA
NKLR

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

Share on Social Networks: